Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock Has Consensus Price Target of $91.20

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has been assigned a consensus rating of “Moderate Buy” from the thirteen research firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $91.20.

HALO has been the topic of a number of recent analyst reports. TD Cowen boosted their price objective on Halozyme Therapeutics from $96.00 to $105.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Wells Fargo & Company raised their price objective on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Citizens Jmp lifted their price objective on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the company a “market outperform” rating in a research note on Friday, August 7th. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Finally, HC Wainwright reissued a “buy” rating and set a $115.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday, September 2nd.

Insider Activity at Halozyme Therapeutics

In other news, Director Matthew L. Posard sold 18,996 shares of the stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $107.74, for a total transaction of $2,046,629.04. Following the completion of the transaction, the director directly owned 58,839 shares of the company’s stock, valued at $6,339,313.86. This represents a 24.41% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $107.43, for a total value of $2,148,600.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $82,482,605.40. This trade represents a 2.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 87,775 shares of company stock valued at $9,311,844. 2.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Twin Capital Management Inc. increased its stake in Halozyme Therapeutics by 1.4% during the 1st quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company’s stock worth $738,000 after buying an additional 161 shares during the period. First Citizens Bank & Trust Co. raised its stake in Halozyme Therapeutics by 2.0% in the first quarter. First Citizens Bank & Trust Co. now owns 9,088 shares of the biopharmaceutical company’s stock valued at $587,000 after buying an additional 175 shares in the last quarter. Nations Financial Group Inc. IA ADV lifted its holdings in Halozyme Therapeutics by 1.2% during the 1st quarter. Nations Financial Group Inc. IA ADV now owns 15,177 shares of the biopharmaceutical company’s stock worth $981,000 after buying an additional 183 shares during the last quarter. Janney Montgomery Scott LLC lifted its holdings in Halozyme Therapeutics by 0.8% during the 1st quarter. Janney Montgomery Scott LLC now owns 25,373 shares of the biopharmaceutical company’s stock worth $1,640,000 after buying an additional 202 shares during the last quarter. Finally, Tema ETFs LLC boosted its position in shares of Halozyme Therapeutics by 0.6% during the 2nd quarter. Tema ETFs LLC now owns 32,598 shares of the biopharmaceutical company’s stock worth $2,551,000 after acquiring an additional 210 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock opened at $109.86 on Wednesday. The company has a 50 day moving average of $103.50 and a 200-day moving average of $81.45. The company has a market cap of $12.47 billion, a PE ratio of 32.79, a price-to-earnings-growth ratio of 0.41 and a beta of 0.88. Halozyme Therapeutics has a 1-year low of $61.22 and a 1-year high of $116.85. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. The business had revenue of $481.00 million during the quarter, compared to analysts’ expectations of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The business’s revenue for the quarter was up 47.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, equities research analysts forecast that Halozyme Therapeutics will post 8.25 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.